Laboratoires Goemar S.a.

University of Louisville Research Foundation

Oklahoma Medical Research Foundation

Laboratoire Goemar Sa

Vaclav Vetvicka

Jean-Claude Yvin

Martin Fusek

Edouard Andre Panak

Jarmila Zidkova

Methods for diagnosing a cancer in a subject are provided that include determining an amount of autoantibodies immunoreactive to procathepsin D (pCD) in a sample obtained from the subject. Further provided are systems for diagnosing a cancer in a subject that include an autoantibody immunoreactive pCD antigen and a means for detecting binding of an autoantibody to the antigen.

Systems and methods for diagnosis and prognosis of cancer

Chemotherapeutic antineoplastic method comprising administration of an effective amount of an antineoplastic agent in conjunction with an effective amount of a &#x3b2;-1,3 glucan.

Chemotherapeutic antineoplastic treatment

The present invention relates to compositions and methods for treating humans and warm-blood animals suffering from cancer. More particularly, a therapeutical treatment in which a monoclonal antibody is administered with either &#x3b2;-(1,3)-glucan like laminarin or a oligo-&#x3b2;-(1,3)-glucan and a pharmaceutically acceptable carrier, to patients suffering from cancer are described.

Therapeutical combination against cancer

Therapeutical method comprising administration to a patient of an effective amount of especially soluble laminarin for the treatment of tumors and more generally of cancers of the group comprising breast cancer, lung cancer, oesophagus cancer, stomach cancer, intestine and colon cancers, and for the treatment of viral, bacterial and fungal diseases as well as diseases related to immunostimulant deficiencies of human beings and warm-blood animals.

Therapeutical treatments

Human procathepsin D was demonstrated to be mitogenic for breast cancer cells but not normal cells. The activation peptide of the procathepsin D appears to be responsible, since inhibition of enhancement of proliferation of breast cancer cells can be obtained by inhibition of the activation peptide through the use of an agent such as an antibody immunoreactive with the activation peptide.

Growing community of inventors

Louisville, KY, United States of America

Vaclav Vetvicka